Our Team

With  deep knowledge of the cannabis plant and the complex and regulated medicinal cannabis ecosystem, our team will draw upon years of experience and an extensive network of contacts to help us identify and evaluate promising opportunities for investment and for organic growth.

Directors

Sharon Segal - Non-Executive Chair

Sharon Segal has over 20 years' experience in investment markets having spent the early part of her investment career with Deutsche Bank as a sell side equities analyst and then with Aviva Investors as a UK Small-Mid Cap Fund Manager, responsible for c£1 billion in assets under management. Subsequently she led the Regulated Fund of Funds team at Fitzwilliam Asset Management and was the lead Fund Manager of the award-winning fund, Fitzwilliam Balanced Managed Fund and has also held an 'AA' rating from Citywire.

Currently, Sharon is Finance Director at Patty & Bun, a Burger Chain Restaurant Group. She has also previously worked at The ONE Group as Director of Finance, having joined the business in 2011, in order to open the UK/European office and head up the European expansion. The ONE Group is a global leader in the hospitality industry and the creator of the international restaurants brand STK. More recent roles include Finance Director for Safestay plc and The Allbright Group. Currently a NED at JW3, the first Jewish Community Centre and arts venue of its kind to exist in London.

Sharon holds a BA (Hons) in Economics from Manchester University, an MA in Demography from the Hebrew University in Jerusalem and is an MBA graduate from the London Business School.

Chana Greenberg - Chief Executive Officer

Chana Greenberg has 20 years’ experience in the start-up and innovation space. She was business development lead at the Centre for Medicinal Cannabis from early 2019 and was most recently VP Business Development at a Canadian LP to build the supply chain of their API licensed CBD for the pharmaceutical (human and veterinary), athletic and health and wellness markets. Chana is passionate about promoting the knowledge of the benefits of cannabis-based products to improve health and wellbeing.

Before transitioning to the medical cannabis industry, Chana worked in traditional investment banking at Barclays and JP Morgan to Buttonwood Capital, a hedge fund founded by a former Goldman Sachs partner, where she researched artificial spinal discs and dental implants. She was until recently Vice Chair of Hadassah UK, supporting Hadassah Hospital, Jerusalem, which shares a campus with the Hebrew University, both pioneers in medicinal cannabis for over 60 years.

Chana holds a BA (Hons) in Business Studies from the University of Westminster, an MPhil in Finance from the University of Cambridge and completed SAID Business School's Private Equity Program at the University of Oxford.

Gavin Sathianathan - Investment Strategy Director

Gavin Sathianathan is a recognised advocate for the European cannabis industry. Gavin is the CEO of Alta Flora, a digital health and telemedicine platform focused on novel therapeutics including medical cannabis. Gavin is also co-founder and non-executive director of Oxford Cannabinoid Technologies (OCT), a bio-pharmaceutical business established in conjunction with the University of Oxford.

Gavin has been an advisor to the All Party Parliamentary Group on medical cannabis, regularly works with investors on the evolution of the cannabis market and has advised multiple FTSE 100 CPG companies. He was profiled in the Times of London as “Britain’s Cannabis Capitalist” and named as “marijuana magnate” by The Spectator. Gavin started his career at Bain & Company, spending four years in London before moving to Delhi as part of the founding team of Bain's Indian operation. Gavin then pursued a career in the digital media industry, initially in content creation at Endemol before joining Facebook in Europe as one of the early team to grow the business ahead of the IPO. He was also Managing Director at Tesco, focused on technology, data, and digital media.

Gavin has a degree in Chemical Engineering from Imperial College, London, and an MBA from Harvard Business School.

Toby Shillito - Chief Business Development Officer

Toby has been designing and operating licensed facilities to cultivate Medical Cannabis in Europe over the past 7 years, assessing the value of many technological innovations in this space. He is knowledgable about the business models that are likely to succeed in the post-prohibition era and keen to assist Cannabis companies to operate within their social and environmental responsibilities

Medicinal Cannabis Technical Advisory Board

Martin Scurr - MRCS, MB BS, FRCGP, FRCP

Martin Scurr was educated at Stonyhurst College and Westminster Medical School. He commenced private practice in the centre of London, was the opening Medical Director of St John's Hospice at the Hospital of St John & St Elizabeth, subsequently appointed as Physician to Westminster Cathedral taking responsibility for the care of many senior Catholic Clergy - leading to a lifetime commitment to the care of those leading religious lives, of whatever denomination. He was appointed Papal Doctor for the 1982 visit of Pope John Paul II. Following appointment as Chairman of the Independent Doctors Forum in 2003, he was appointed as medical columnist for the Daily Mail where he continues to be their Medical Correspondent. Dr Scurr is also Medical Advisor, Script Advisor, for the ITV light Entertainment series “Doc Martin”. The tenth series of this television programme is now in preparation, whilst Dr Scurr is affectionately known as “Doc Martin” amongst readers and viewers.

Dr. Stuart Ungar - MB,BS,(U.Lond), MRCP(UK),MRCS(ENG)

After pursuing post-graduate studies in General Medicine and research in biochemical neuropsychopharmacology  at The Royal Post-Graduate Medical School Dr. Ungar was in practice as a General Physician at The Princess Grace Hospital. Jointly with Dr. Raymond Prudo, Dr. Ungar founded a start-up company, The Doctors Laboratory PLC, a general pathology laboratory, that introduced a new paradigm in service provision for clinicians and pharmaceutical organizations throughout the United Kingdom and abroad. During his tenure as Chairman and a Board Director, The Doctors Laboratory PLC grew very substantially and was sold to Sonic Healthcare in 2002. Currently he is a Director of a NASDAQ quoted biopharmaceutical company creating drugs for acute and chronic orphan inflammatory diseases by modulating one or both of the complement C5 and leukotriene pathways. Dr. Ungar qualified in medicine, with additional qualifications in medical biochemistry at the Royal Free Hospital, London and was admitted as a member to The Royal College of Physicians. Dr. Ungar is a Life Fellow of The Royal Society of Medicine and is a founder and former Vice-President of The Independent Doctors Federation.

Dr. Peter Feldschreiber

Dr. Peter Feldschreiber is dual qualified as a barrister and physician. He specialises in medical and healthcare law including medical products liability, pharmaceutical and medical devices regulatory law, clinical negligence and personal injury and medically related employment litigation.

Casework includes the Aspirin Reyes Syndrome product liability litigation, Atomic Veterans Litigation, the morning after pill litigation, the Seroquel litigation, Foetal Anti- convulsant Syndrome Litigation, Cochlear Implants and Cardiac Stent Litigations and judicial review and references to the ECJ on pharmaceutical regulatory issues. He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Medicines and Healthcare products Regulatory Agency, Department of Health.

Dr Feldschreiber is General Editor of The Law and Regulation of Medicines (Oxford University Press) and is Consultant Editor for the Volume on Medical Products for Halsburys Laws of England and the Lexis Nexis series on updates of UK and European Law. He is co-author of the chapter on the regulation of healthcare products in Butterworths Healthcare Law and Practice. Peter is also the Visiting Senior Lecturer in Pharmaceutical Science at King's College London.

He is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury. He has also published extensively on the law of causation and European regulatory procedure. He has published research into the repair of DNA following ionising radiation whilst working at the Institute of Cancer Research. He is also a member of the Expert Witness Institute.